Literature DB >> 27186517

Prognostic value of the expression of estrogen receptor β in patients with non-small cell lung cancer: a meta-analysis.

Lihong Ma1, Ping Zhan1, Yafang Liu1, Zejun Zhou1, Qingqing Zhu1, Yingying Miu1, Xiaoxia Wang1, Jiajia Jin1, Qian Li1, Tangfeng Lv1, Yong Song1.   

Abstract

BACKGROUND: Lung cancer remains the leading cause of cancer-related deaths in men and the second leading cause in women worldwide. It is becoming increasingly clear that estrogen and estrogen receptors are involved in the pathogenesis and development of lung cancer. However, observational studies on the prognostic role of estrogen receptor β (ERβ) in non-small cell lung cancer (NSCLC) are controversial.
METHODS: To clarify the impact of ERβ in NSCLC survival, we performed this meta-analysis that included eligible studies. The combined hazard ratios (HR) and their corresponding 95% confidence intervals (CIs) were calculated in terms of overall survival.
RESULTS: A total of eleven studies with 3,300 patients were evaluable for this meta-analysis. Our results suggested that ERβ overexpression had no relationship on survival of patients with NSCLC, the HR (95% CI) was 1.000 (0.954-1.047) overall. Moreover, there was no heterogeneity between the studies.
CONCLUSIONS: ERβ overexpression indicates no relationship of prognosis for patients with NSCLC.

Entities:  

Keywords:  Estrogen receptor β (ERβ); lung cancer; meta-analysis; prognosis

Year:  2016        PMID: 27186517      PMCID: PMC4858573          DOI: 10.21037/tlcr.2016.04.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  38 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

3.  Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.

Authors:  K Paech; P Webb; G G Kuiper; S Nilsson; J Gustafsson; P J Kushner; T S Scanlan
Journal:  Science       Date:  1997-09-05       Impact factor: 47.728

4.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

5.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

6.  Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.

Authors:  Laura P Stabile; Jennifer S Lyker; Christopher T Gubish; Weiping Zhang; Jennifer R Grandis; Jill M Siegfried
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

7.  Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex.

Authors:  Ann G Schwartz; Geoffrey M Prysak; Valerie Murphy; Fulvio Lonardo; Harvey Pass; Jan Schwartz; Sam Brooks
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

8.  Role of hormone receptor expression in patients with advanced-stage lung cancer treated with chemotherapy.

Authors:  Valentina Monica; Marina Longo; Barbara Felice; Giorgio V Scagliotti; Mauro Papotti; Silvia Novello
Journal:  Clin Lung Cancer       Date:  2012-06-02       Impact factor: 4.785

Review 9.  Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways.

Authors:  Stephen Safe; Kyounghyun Kim; Kyoungkim Kim
Journal:  J Mol Endocrinol       Date:  2008-09-04       Impact factor: 5.098

10.  Estrogen receptor 1 gene expression and its combination with estrogen receptor 2 or aromatase expression predicts survival in non-small cell lung cancer.

Authors:  Unai Aresti; Sergio Carrera; Eluska Iruarrizaga; Natalia Fuente; Ines Marrodan; Abigail Ruiz de Lobera; Alberto Muñoz; Aitziber Buque; Elizabeth Condori; Irene Ugalde; Begoña Calvo; Guillermo López Vivanco
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

View more
  14 in total

1.  The prevalence and prognostic significance of estrogen receptor beta expression in non-small cell lung cancer.

Authors:  Emeka K Enwere; Michelle L Dean; Haocheng Li; Adrijana D'Silva; D Gwyn Bebb
Journal:  Transl Lung Cancer Res       Date:  2020-06

Review 2.  Influence of estrogen in non-small cell lung cancer and its clinical implications.

Authors:  Vianey Rodriguez-Lara; Juan-Manuel Hernandez-Martinez; Oscar Arrieta
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

3.  Regulation of submaxillary gland androgen-regulated protein 3A via estrogen receptor 2 in radioresistant head and neck squamous cell carcinoma cells.

Authors:  Jennifer Grünow; Chao Rong; Jan Hischmann; Karim Zaoui; Christa Flechtenmacher; Klaus-Josef Weber; Peter Plinkert; Jochen Hess
Journal:  J Exp Clin Cancer Res       Date:  2017-02-06

Review 4.  Estrogen, Estrogen Receptor and Lung Cancer.

Authors:  Li-Han Hsu; Nei-Min Chu; Shu-Huei Kao
Journal:  Int J Mol Sci       Date:  2017-08-05       Impact factor: 5.923

5.  CLPTM1L induces estrogen receptor β signaling-mediated radioresistance in non-small cell lung cancer cells.

Authors:  Hang Li; Jun Che; Mian Jiang; Ming Cui; Guoxing Feng; Jiali Dong; Shuqin Zhang; Lu Lu; Weili Liu; Saijun Fan
Journal:  Cell Commun Signal       Date:  2020-09-17       Impact factor: 5.712

6.  Synaptotagmin 7 in twist-related protein 1-mediated epithelial - Mesenchymal transition of non-small cell lung cancer.

Authors:  Xiao Liu; Chunyu Li; Yie Yang; Xiaoxia Liu; Rui Li; Mengyu Zhang; Yunhong Yin; Yiqing Qu
Journal:  EBioMedicine       Date:  2019-08-06       Impact factor: 8.143

7.  Estrogen receptor β promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer.

Authors:  Weiwei Yu; Jie Ding; Maio He; Yuan Chen; Ronghao Wang; Zhenwei Han; Emily Z Xing; Cuntai Zhang; Shuyuan Yeh
Journal:  Oncogene       Date:  2018-09-24       Impact factor: 8.756

8.  Contribution of upregulated dipeptidyl peptidase 9 (DPP9) in promoting tumoregenicity, metastasis and the prediction of poor prognosis in non-small cell lung cancer (NSCLC).

Authors:  Zhiyuan Tang; Jun Li; Qin Shen; Jian Feng; Hua Liu; Wei Wang; Liqin Xu; Guanglin Shi; Xumei Ye; Min Ge; Xiaoyu Zhou; Songshi Ni
Journal:  Int J Cancer       Date:  2017-02-02       Impact factor: 7.396

9.  Sex hormone receptor expression and survival in esophageal adenocarcinoma: a prospective cohort study.

Authors:  Úna C McMenamin; James Trainor; Helen G Coleman; Damian T McManus; Stephen McQuaid; Victoria Bingham; Jacqueline James; Manuel Salto-Tellez; Brian T Johnston; Richard C Turkington
Journal:  Oncotarget       Date:  2018-10-19

10.  Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma.

Authors:  Hendrik Seeliger; Ioannis Pozios; Gerald Assmann; Yue Zhao; Mario H Müller; Thomas Knösel; Martin E Kreis; Christiane J Bruns
Journal:  BMC Cancer       Date:  2018-10-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.